Skip to main content

Table 4 Comparative analysis of the associations between PCT, hsCRP and incident mortality

From: Plasma procalcitonin is associated with all-cause and cancer mortality in apparently healthy men: a prospective population-based study

Subjects Outcome PCT hsCRP
HR (95% CI)a P HR (95% CI)a P
All subjects All-cause mortality 1.15 (1.04 to 1.26) 0.006** 1.08 (0.98 to 1.19) 0.100
Cancer mortality 1.23 (1.06 to 1.41) 0.005** 1.02 (0.89 to 1.16) 0.788
CVD mortality 1.08 (0.89 to 1.30) 0.425 1.24 (1.03 to 1.49) 0.025*
Mortality from causes other than cancer and CVD 1.15 (0.95 to 1.39) 0.161 1.07 (0.89 to 1.28) 0.483
Men All-cause mortality 1.13 (1.00 to 1.27) 0.047* 1.09 (0.97 to 1.23) 0.156
Cancer mortality 1.29 (1.08 to 1.54) 0.006** 0.96 (0.80 to 1.14) 0.632
CVD mortality 1.04 (0.83 to 1.30) 0.741 1.30 (1.01 to 1.66) 0.037*
Mortality from causes other than cancer and CVD 1.07 (0.86 to 1.34) 0.556 1.16 (0.92 to 1.47) 0.220
Women All-cause mortality 1.13 (0.97 to 1.32) 0.106 1.07 (0.92 to 1.24) 0.362
Cancer mortality 1.09 (0.88 to 1.35) 0.430 1.13 (0.92 to 1.38) 0.261
CVD mortality 1.19 (0.87 to 1.62) 0.286 1.13 (0.84 to 1.51) 0.433
Mortality from causes other than cancer and CVD 1.21 (0.87 to 1.67) 0.251 0.92 (0.68 to 1.23) 0.568
  1. Cox regression analysis adjusted for age, sex, hypertension, diabetes, LDL, HDL, TG, renal function, BMI and smoking. aThe HR values are expressed as mean HR per quartile of the respective biomarker. BMI, body mass index; CI, confidence interval; CVD, cardiovascular disease; HDL, high-density lipoprotein; HR, hazard ratio; hsCRP, high sensitivity C-reactive protein; LDL, low-density lipoprotein; PCT, procalcitonin; TG, triglycerides. *P <0.05, **P <0.01.
\